PIM1 and Miyoshi myopathy: Furthermore, a recent study found that bortezomib treatment increases PIM half-life by prevention of PIM proteasomal degradation and therefore, the inclusion of a PIM kinase inhibitor in a bortezomib-based regimen could be effective in MM treatment [61].